Repligen (NASDAQ:RGEN) PT Lowered to $200.00 at JPMorgan Chase & Co.

Repligen (NASDAQ:RGEN) had its target price reduced by JPMorgan Chase & Co. from $230.00 to $200.00 in a research report released on Thursday morning, Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the biotechnology company’s stock.

A number of other equities analysts have also recently issued reports on the stock. Stifel Nicolaus increased their price objective on shares of Repligen from $165.00 to $207.00 and gave the stock a buy rating in a research report on Thursday, February 22nd. KeyCorp increased their price target on Repligen from $210.00 to $220.00 and gave the stock an overweight rating in a report on Thursday, February 15th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, Repligen presently has a consensus rating of Moderate Buy and a consensus price target of $197.75.

Repligen Trading Up 0.4 %

Shares of Repligen stock traded up $0.74 on Thursday, hitting $167.05. 454,984 shares of the company’s stock traded hands, compared to its average volume of 538,521. The company has a market capitalization of $9.33 billion, a price-to-earnings ratio of 668.23, a price-to-earnings-growth ratio of 5.44 and a beta of 1.03. The company has a fifty day moving average of $180.81 and a two-hundred day moving average of $173.90. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.35 and a quick ratio of 5.75. Repligen has a one year low of $110.45 and a one year high of $211.13.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.28 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.01). The company had revenue of $151.31 million for the quarter, compared to analyst estimates of $150.06 million. Repligen had a return on equity of 3.95% and a net margin of 2.44%. The business’s quarterly revenue was down 17.1% compared to the same quarter last year. During the same period last year, the business earned $0.64 EPS. As a group, sell-side analysts expect that Repligen will post 1.46 earnings per share for the current year.

Insider Activity at Repligen

In other Repligen news, Director Karen A. Dawes sold 1,000 shares of the firm’s stock in a transaction on Tuesday, February 27th. The stock was sold at an average price of $193.35, for a total transaction of $193,350.00. Following the transaction, the director now directly owns 87,367 shares in the company, valued at approximately $16,892,409.45. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Repligen news, CEO Anthony Hunt sold 16,707 shares of the stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $197.44, for a total value of $3,298,630.08. Following the completion of the sale, the chief executive officer now owns 185,249 shares in the company, valued at approximately $36,575,562.56. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Karen A. Dawes sold 1,000 shares of the stock in a transaction dated Tuesday, February 27th. The shares were sold at an average price of $193.35, for a total transaction of $193,350.00. Following the completion of the sale, the director now owns 87,367 shares of the company’s stock, valued at approximately $16,892,409.45. The disclosure for this sale can be found here. Insiders have sold a total of 25,597 shares of company stock valued at $5,039,532 over the last 90 days. Insiders own 1.20% of the company’s stock.

Institutional Investors Weigh In On Repligen

Several institutional investors and hedge funds have recently added to or reduced their stakes in RGEN. Parnassus Investments LLC purchased a new stake in Repligen in the 3rd quarter valued at about $87,475,000. Norges Bank bought a new position in Repligen during the fourth quarter valued at $48,208,000. Allspring Global Investments Holdings LLC bought a new position in Repligen during the third quarter valued at $41,540,000. Artisan Partners Limited Partnership grew its holdings in Repligen by 11.3% during the third quarter. Artisan Partners Limited Partnership now owns 1,556,873 shares of the biotechnology company’s stock valued at $247,558,000 after purchasing an additional 157,807 shares during the period. Finally, Bank of New York Mellon Corp grew its holdings in Repligen by 13.0% during the third quarter. Bank of New York Mellon Corp now owns 1,195,629 shares of the biotechnology company’s stock valued at $190,117,000 after purchasing an additional 137,220 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.